Alexi Archambault

Regeneron Pharmaceuticals, Inc.

Poster(s):

• (C-211) Immune-mediated adverse events in patients with high-risk melanoma receiving immune checkpoint inhibitors in adjuvant and first-line treatment settings: a real-world analysis
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (C-207) Implementing robust machine learning pipelines with real-world data: identifying predictors of immune mediated adverse events among patients with advanced melanoma treated with immune checkpoint inhibitors
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (B-188) Safety and Effectiveness of Cemiplimab in Combination with Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: An Ongoing Real World Evidence Study
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET